Review



igf1  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems igf1
    Igf1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 399 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/Recombinant+Human+IGF-I%2FIGF-1+Protein%2C+CF/pm42805170-961-43-45
    Average 96 stars, based on 399 article reviews
    igf1 - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Insulin-like growth factor-1/insulin-like growth factor-1 receptor signalling in macrophages facilitates recovery from acute lung injury.
    Article Snippet: .. We intratracheally administered 1 μg per body of recombinant IGF-1 (R&D systems, Minneapolis, MN, USA) or 20 μg per body of JB1 (Sigma-Aldrich) on days 3 and 4 after LPS injection, with a vehicle control group included, followed by harvest on day 5. ..

    Article Title: Macrophage-derived insulin-like growth factor-1 is a key neurotrophic and nerve-sensitizing factor in pain associated with endometriosis
    Article Snippet: Whole-ganglion explants were plated onto poly- D -lysine- and Matrigel-coated wells (BD Biosciences) in 48-well plates and incubated in DRG medium (high-glucose DMEM supplemented with 0.01% penicillin-streptomycin, 10% fetal calf serum). .. Positive controls were supplemented with nerve growth factor (NGF) (Bio-Rad, Hercules, CA, USA) plus recombinant IGF-1 (R&D Systems, Minneapolis, MN, USA) (2–200 ng/ml) ± 125–500 nM Picropodophyllin (PPP; Tocris Bioscience, Bristol, United Kingdom). ..

    Article Title: Study on Factors Affecting the Performance of a CRISPR/Cas-Assisted New Immunoassay: Detection of Salivary Insulin as an Example
    Article Snippet: .. Goat anti-mouse IgG (GTX77316, GeneTex), goat anti-rabbit IgG (GTX77061, GeneTex), streptavidin (85,878, Sigma Aldrich), streptavidin conjugation kit (ab102921, Abcam), Amicon® Ultra filters low-binding PES filter with 30 k molecular separation pores (UFC503096, Millipore), agarose powder (4,718, Sigma Aldrich), TAE buffer (Tris/Acetic Acid/EDTA) (1,610,743, Bio-Rad), SYBG Gold dye (41,003, Thermo Fisher Scientific), low–molecular weight DNA ladder (B7025, New England Biolabs Inc.), PowerPacTM basic power supply (1,645,050, Bio-Rad), Mini-Sub Cell GT Cell (1,704,406, Bio-Rad), Gel DocTM EZ System (1708270EDU, Bio-Rad), SpectraMax iD5 Multi-Mode Microplate Reader (Molecular Devices), recombinant human insulin (I2643, Sigma Aldrich), recombinant human IFN-γ (285-IF, R&D Systems), recombinant human IP10 (ab9810, Abcam), recombinant IL-6 (206-IL, R&D Systems), recombinant TNF-α (210-TA, R&D Systems), recombinant IGF-1 (291-G1, R&D Systems), recombinant human proinsulin C-peptide (NBP235211, Novus Biologicals), rabbit polyclonal anti-human insulin (ab53591, Abcam), rabbit polyclonal anti-human human insulin antibody (NBP1-87485, Novus Biologicals), rabbit polyclonal anti-human insulin (biotin) (ab53592, Abcam), mouse monoclonal anti-human insulin (ab6995, Abcam), and mouse monoclonal anti-human human insulin antibody (NBP100-73008, Novus Biologicals). ..

    Article Title: Macrophage‐derived insulin‐like growth factor‐1 is a key neurotrophic and nerve‐sensitizing factor in pain associated with endometriosis
    Article Snippet: .. CA, USA) plus recombinant IGF-1 (R&D Systems, Minneapolis, MN,USA) (2–200 ng/ml)6 125–500 nMPicropodophyllin (PPP; Tocris Bioscience, Bristol, United Kingdom). ..

    Article Title: Method for differentiation into retinal ganglion cells from stem cells
    Article Snippet: and SSEA-4 (Chemicon, Temecula, Calif.), which are antigens specific to undifferentiated human induced pluripotent stem cells, was conducted at regular intervals of time to monitor the degree of differentiation. .. To the human embryonic stem cells or human induced pluripotent stem cells in the 6-well ultra-low attachment plates was added a medium for inducing differentiation into eye field precursors [DMEM/F12, 10% KnockOut serum replacement, 1 mM L-glutamine, 0.1 mM nonessential amino acids, 0.1 mM mercaptoethanol, 1% B27 supplement (Invitrogen), 1 ng/mL recombinant Noggin (R&D Systems), 1 ng/mL recombinant Dkk-1 (recombinant Dickkopf-1, R&D Systems), and 5 ng/mL recombinant IGF-1 (recombinant insulin-like growth factor-1, R&D Systems)]. ..

    Article Title: Method for differentiation into retinal ganglion cells from stem cells
    Article Snippet: First, human embryonic stem cells or human induced pluripotent stem cells cultured by the method of Example 1 were separated from the mouse embryonic fibroblasts and transferred onto 6-well ultra-low attachment plates (Corning Incorporated, Corning, N.Y., USA), respectively. .. To the human embryonic stem cells or human induced pluripotent stem cells in the 6-well ultra-low attachment plates was added a medium for inducing differentiation into eye field precursors [DMEM/F12, 10% KnockOut serum replacement, 1 mM L-glutamine, 0.1 mM nonessential amino acids, 0.1 mM mercaptoethanol, 1% B27 supplement (Invitrogen), 1 ng/mL recombinant Noggin (R&D Systems), 1 ng/mL recombinant Dkk-1 (recombinant Dickkopf-1, R&D Systems), and 5 ng/mL recombinant IGF-1 (recombinant insulin-like growth factor-1, R&D Systems)]. ..

    Article Title: Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma
    Article Snippet: .. To investigate the role of IGF/PI3K signaling in neuronal cytolysis, recombinant IGF-1 (R & D Systems) was added into the culture media of neurons 30 min before the replacement of conditioned media from microglias. ..

    Injection:

    Article Title: Insulin-like growth factor-1/insulin-like growth factor-1 receptor signalling in macrophages facilitates recovery from acute lung injury.
    Article Snippet: .. We intratracheally administered 1 μg per body of recombinant IGF-1 (R&D systems, Minneapolis, MN, USA) or 20 μg per body of JB1 (Sigma-Aldrich) on days 3 and 4 after LPS injection, with a vehicle control group included, followed by harvest on day 5. ..

    Control:

    Article Title: Insulin-like growth factor-1/insulin-like growth factor-1 receptor signalling in macrophages facilitates recovery from acute lung injury.
    Article Snippet: .. We intratracheally administered 1 μg per body of recombinant IGF-1 (R&D systems, Minneapolis, MN, USA) or 20 μg per body of JB1 (Sigma-Aldrich) on days 3 and 4 after LPS injection, with a vehicle control group included, followed by harvest on day 5. ..

    Conjugation Assay:

    Article Title: Study on Factors Affecting the Performance of a CRISPR/Cas-Assisted New Immunoassay: Detection of Salivary Insulin as an Example
    Article Snippet: .. Goat anti-mouse IgG (GTX77316, GeneTex), goat anti-rabbit IgG (GTX77061, GeneTex), streptavidin (85,878, Sigma Aldrich), streptavidin conjugation kit (ab102921, Abcam), Amicon® Ultra filters low-binding PES filter with 30 k molecular separation pores (UFC503096, Millipore), agarose powder (4,718, Sigma Aldrich), TAE buffer (Tris/Acetic Acid/EDTA) (1,610,743, Bio-Rad), SYBG Gold dye (41,003, Thermo Fisher Scientific), low–molecular weight DNA ladder (B7025, New England Biolabs Inc.), PowerPacTM basic power supply (1,645,050, Bio-Rad), Mini-Sub Cell GT Cell (1,704,406, Bio-Rad), Gel DocTM EZ System (1708270EDU, Bio-Rad), SpectraMax iD5 Multi-Mode Microplate Reader (Molecular Devices), recombinant human insulin (I2643, Sigma Aldrich), recombinant human IFN-γ (285-IF, R&D Systems), recombinant human IP10 (ab9810, Abcam), recombinant IL-6 (206-IL, R&D Systems), recombinant TNF-α (210-TA, R&D Systems), recombinant IGF-1 (291-G1, R&D Systems), recombinant human proinsulin C-peptide (NBP235211, Novus Biologicals), rabbit polyclonal anti-human insulin (ab53591, Abcam), rabbit polyclonal anti-human human insulin antibody (NBP1-87485, Novus Biologicals), rabbit polyclonal anti-human insulin (biotin) (ab53592, Abcam), mouse monoclonal anti-human insulin (ab6995, Abcam), and mouse monoclonal anti-human human insulin antibody (NBP100-73008, Novus Biologicals). ..

    other:

    Article Title: Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2
    Article Snippet: Human IRS deletions and chimeras were generated by PCR amplification using Q5 Hot Start High-Fidelity DNA polymerase (M0493S; New England BioLabs), and the PCR products were ligated into vectors using a Quick Ligation kit (M2200S; New England BioLabs).

    Knock-Out:

    Article Title: Method for differentiation into retinal ganglion cells from stem cells
    Article Snippet: and SSEA-4 (Chemicon, Temecula, Calif.), which are antigens specific to undifferentiated human induced pluripotent stem cells, was conducted at regular intervals of time to monitor the degree of differentiation. .. To the human embryonic stem cells or human induced pluripotent stem cells in the 6-well ultra-low attachment plates was added a medium for inducing differentiation into eye field precursors [DMEM/F12, 10% KnockOut serum replacement, 1 mM L-glutamine, 0.1 mM nonessential amino acids, 0.1 mM mercaptoethanol, 1% B27 supplement (Invitrogen), 1 ng/mL recombinant Noggin (R&D Systems), 1 ng/mL recombinant Dkk-1 (recombinant Dickkopf-1, R&D Systems), and 5 ng/mL recombinant IGF-1 (recombinant insulin-like growth factor-1, R&D Systems)]. ..

    Article Title: Method for differentiation into retinal ganglion cells from stem cells
    Article Snippet: First, human embryonic stem cells or human induced pluripotent stem cells cultured by the method of Example 1 were separated from the mouse embryonic fibroblasts and transferred onto 6-well ultra-low attachment plates (Corning Incorporated, Corning, N.Y., USA), respectively. .. To the human embryonic stem cells or human induced pluripotent stem cells in the 6-well ultra-low attachment plates was added a medium for inducing differentiation into eye field precursors [DMEM/F12, 10% KnockOut serum replacement, 1 mM L-glutamine, 0.1 mM nonessential amino acids, 0.1 mM mercaptoethanol, 1% B27 supplement (Invitrogen), 1 ng/mL recombinant Noggin (R&D Systems), 1 ng/mL recombinant Dkk-1 (recombinant Dickkopf-1, R&D Systems), and 5 ng/mL recombinant IGF-1 (recombinant insulin-like growth factor-1, R&D Systems)]. ..



    Similar Products

    96
    Bio-Techne corporation recombinant human igf-i/igf-1 protein, cf
    Recombinant Human Igf I/Igf 1 Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/Recombinant+Human+IGF-I%2FIGF-1+Protein%2C+CF/custom%40291-g1%4042497058
    Average 96 stars, based on 1 article reviews
    recombinant human igf-i/igf-1 protein, cf - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    MedChemExpress recombinant igf1
    (a) Experimental design of the conditioned-medium (CM) model. Mice received daily intraperitoneal injections of TRAMP-C1 CM or matched blank medium (Control) for 2 weeks; BM was collected after 1 or 2 weeks. (b) Flow-cytometric quantification of CCR3-positive neutrophils, CD8Temra cells, intermediate monocytes (intMono) and non-classical monocytes (ncMono) during niche establishment. Each dot represents one mouse; for CCR3 neutrophils, intMono and ncMono measurements, n = 6, 7 and 7 mice for Control, 1 week and 2 weeks groups, respectively. For CD8 T cells, n = 3 mice per group. (c) Representative multiplex immunofluorescence images of BM stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (d) Frequency of CCR3-positive Ly6G-positive neutrophils in BM, liver, lung, peripheral blood (PB) and spleen from sham-operated and orthotopic prostate-tumor-bearing mice. Each dot represents one mouse; n = 3 mice per group. (e) Differential expression in epithelial cells from primary prostate cancer versus normal prostate datasets; selected tumor-secreted factors are labeled. (f) Activity of <t>IGF1-,</t> CXCL8-and ERBB-family downstream gene modules across neutrophil states. (g) Representative immunohistochemical staining of IGF1 in normal prostate and prostate cancer tissues from patients with low/medium risk, high risk or established bone metastasis. Scale bar, 200 µm. (h) Quantification of prostate-tissue IGF1 staining and plasma IGF1 bioavailability across normal, low/medium-risk, high-risk and bone-metastatic prostate cancer groups. For tissue IGF1 staining, normal prostate, n = 15 patients; low/medium-risk PCa, n = 16; high-risk PCa, n = 21; bone-metastatic PCa, n = 11. For plasma IGF1 bioavailability, normal prostate, n = 6 patients; low/medium-risk PCa, n = 13; high-risk PCa, n = 14; bone-metastatic PCa, n = 10. (i) Paired plasma IGF1 bioavailability before and after radical prostatectomy (RP); n = 9 matched patient pairs. (j) IGF1 staining in primary prostate cancer tissues and plasma IGF1 bioavailability in patients with advanced localized PCa, stratified according to subsequent bone metastasis development during follow-up (non-BMets, remained free of bone metastasis; BMets, subsequently developed bone metastases). For tissue IGF1 staining, non-BMets, n = 36 patients; BMets, n = 33. For plasma IGF1 bioavailability, non-BMets, n = 18 patients; BMets, n = 8. (k) Flow-cytometric quantification of IGF1R mean fluorescence intensity (MFI) on neutrophils from PB, spleen and BM. Each dot represents one mouse; n = 4, 4 and 3 mice for PB, spleen and BM, respectively. (l) UMAP of epithelial cells in metastatic BM samples. Early and late subtypes were labeled. (m) Diffusion-map and RNA-velocity analysis of epithelial-subtype progression. (n) UMAP feature plots of IGF1 , COL5A2 , ACAD8 , FOS , FOSB and JUN . (o) Malignant epithelial cells from paired primary-prostate cancer and BM samples from patients M8 and M9, shown by cluster identity and tissue-specific density. (p) EMP scores across paired-sample epithelial clusters. (q) Patient-specific diffusion maps with RNA-velocity vectors, colored by cluster identity. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical significance was assessed using two-sided unpaired Student’s t-tests (b,d,h,j,k), a paired Student’s t-test (i), Fisher’s exact tests with multiple-testing correction (e). Student’s t-test P values were adjusted using the Benjamini-Hochberg method where multiple comparisons were performed.
    Recombinant Igf1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/IGF-I%2FIGF-1%2C+Mouse/bio_rxiv__64898__2026__10__08__757800-591-10-14
    Average 94 stars, based on 1 article reviews
    recombinant igf1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    99
    MedChemExpress hy 16658b recombinant mouse igf 1 mce
    (a) Experimental design of the conditioned-medium (CM) model. Mice received daily intraperitoneal injections of TRAMP-C1 CM or matched blank medium (Control) for 2 weeks; BM was collected after 1 or 2 weeks. (b) Flow-cytometric quantification of CCR3-positive neutrophils, CD8Temra cells, intermediate monocytes (intMono) and non-classical monocytes (ncMono) during niche establishment. Each dot represents one mouse; for CCR3 neutrophils, intMono and ncMono measurements, n = 6, 7 and 7 mice for Control, 1 week and 2 weeks groups, respectively. For CD8 T cells, n = 3 mice per group. (c) Representative multiplex immunofluorescence images of BM stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (d) Frequency of CCR3-positive Ly6G-positive neutrophils in BM, liver, lung, peripheral blood (PB) and spleen from sham-operated and orthotopic prostate-tumor-bearing mice. Each dot represents one mouse; n = 3 mice per group. (e) Differential expression in epithelial cells from primary prostate cancer versus normal prostate datasets; selected tumor-secreted factors are labeled. (f) Activity of <t>IGF1-,</t> CXCL8-and ERBB-family downstream gene modules across neutrophil states. (g) Representative immunohistochemical staining of IGF1 in normal prostate and prostate cancer tissues from patients with low/medium risk, high risk or established bone metastasis. Scale bar, 200 µm. (h) Quantification of prostate-tissue IGF1 staining and plasma IGF1 bioavailability across normal, low/medium-risk, high-risk and bone-metastatic prostate cancer groups. For tissue IGF1 staining, normal prostate, n = 15 patients; low/medium-risk PCa, n = 16; high-risk PCa, n = 21; bone-metastatic PCa, n = 11. For plasma IGF1 bioavailability, normal prostate, n = 6 patients; low/medium-risk PCa, n = 13; high-risk PCa, n = 14; bone-metastatic PCa, n = 10. (i) Paired plasma IGF1 bioavailability before and after radical prostatectomy (RP); n = 9 matched patient pairs. (j) IGF1 staining in primary prostate cancer tissues and plasma IGF1 bioavailability in patients with advanced localized PCa, stratified according to subsequent bone metastasis development during follow-up (non-BMets, remained free of bone metastasis; BMets, subsequently developed bone metastases). For tissue IGF1 staining, non-BMets, n = 36 patients; BMets, n = 33. For plasma IGF1 bioavailability, non-BMets, n = 18 patients; BMets, n = 8. (k) Flow-cytometric quantification of IGF1R mean fluorescence intensity (MFI) on neutrophils from PB, spleen and BM. Each dot represents one mouse; n = 4, 4 and 3 mice for PB, spleen and BM, respectively. (l) UMAP of epithelial cells in metastatic BM samples. Early and late subtypes were labeled. (m) Diffusion-map and RNA-velocity analysis of epithelial-subtype progression. (n) UMAP feature plots of IGF1 , COL5A2 , ACAD8 , FOS , FOSB and JUN . (o) Malignant epithelial cells from paired primary-prostate cancer and BM samples from patients M8 and M9, shown by cluster identity and tissue-specific density. (p) EMP scores across paired-sample epithelial clusters. (q) Patient-specific diffusion maps with RNA-velocity vectors, colored by cluster identity. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical significance was assessed using two-sided unpaired Student’s t-tests (b,d,h,j,k), a paired Student’s t-test (i), Fisher’s exact tests with multiple-testing correction (e). Student’s t-test P values were adjusted using the Benjamini-Hochberg method where multiple comparisons were performed.
    Hy 16658b Recombinant Mouse Igf 1 Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/Z-VAD-FMK/pm42822448-195-68-72
    Average 99 stars, based on 1 article reviews
    hy 16658b recombinant mouse igf 1 mce - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    R&D Systems igf1
    (a) Experimental design of the conditioned-medium (CM) model. Mice received daily intraperitoneal injections of TRAMP-C1 CM or matched blank medium (Control) for 2 weeks; BM was collected after 1 or 2 weeks. (b) Flow-cytometric quantification of CCR3-positive neutrophils, CD8Temra cells, intermediate monocytes (intMono) and non-classical monocytes (ncMono) during niche establishment. Each dot represents one mouse; for CCR3 neutrophils, intMono and ncMono measurements, n = 6, 7 and 7 mice for Control, 1 week and 2 weeks groups, respectively. For CD8 T cells, n = 3 mice per group. (c) Representative multiplex immunofluorescence images of BM stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (d) Frequency of CCR3-positive Ly6G-positive neutrophils in BM, liver, lung, peripheral blood (PB) and spleen from sham-operated and orthotopic prostate-tumor-bearing mice. Each dot represents one mouse; n = 3 mice per group. (e) Differential expression in epithelial cells from primary prostate cancer versus normal prostate datasets; selected tumor-secreted factors are labeled. (f) Activity of <t>IGF1-,</t> CXCL8-and ERBB-family downstream gene modules across neutrophil states. (g) Representative immunohistochemical staining of IGF1 in normal prostate and prostate cancer tissues from patients with low/medium risk, high risk or established bone metastasis. Scale bar, 200 µm. (h) Quantification of prostate-tissue IGF1 staining and plasma IGF1 bioavailability across normal, low/medium-risk, high-risk and bone-metastatic prostate cancer groups. For tissue IGF1 staining, normal prostate, n = 15 patients; low/medium-risk PCa, n = 16; high-risk PCa, n = 21; bone-metastatic PCa, n = 11. For plasma IGF1 bioavailability, normal prostate, n = 6 patients; low/medium-risk PCa, n = 13; high-risk PCa, n = 14; bone-metastatic PCa, n = 10. (i) Paired plasma IGF1 bioavailability before and after radical prostatectomy (RP); n = 9 matched patient pairs. (j) IGF1 staining in primary prostate cancer tissues and plasma IGF1 bioavailability in patients with advanced localized PCa, stratified according to subsequent bone metastasis development during follow-up (non-BMets, remained free of bone metastasis; BMets, subsequently developed bone metastases). For tissue IGF1 staining, non-BMets, n = 36 patients; BMets, n = 33. For plasma IGF1 bioavailability, non-BMets, n = 18 patients; BMets, n = 8. (k) Flow-cytometric quantification of IGF1R mean fluorescence intensity (MFI) on neutrophils from PB, spleen and BM. Each dot represents one mouse; n = 4, 4 and 3 mice for PB, spleen and BM, respectively. (l) UMAP of epithelial cells in metastatic BM samples. Early and late subtypes were labeled. (m) Diffusion-map and RNA-velocity analysis of epithelial-subtype progression. (n) UMAP feature plots of IGF1 , COL5A2 , ACAD8 , FOS , FOSB and JUN . (o) Malignant epithelial cells from paired primary-prostate cancer and BM samples from patients M8 and M9, shown by cluster identity and tissue-specific density. (p) EMP scores across paired-sample epithelial clusters. (q) Patient-specific diffusion maps with RNA-velocity vectors, colored by cluster identity. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical significance was assessed using two-sided unpaired Student’s t-tests (b,d,h,j,k), a paired Student’s t-test (i), Fisher’s exact tests with multiple-testing correction (e). Student’s t-test P values were adjusted using the Benjamini-Hochberg method where multiple comparisons were performed.
    Igf1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/Recombinant+Human+IGF-I%2FIGF-1+Protein%2C+CF/pm42805170-961-43-45
    Average 96 stars, based on 1 article reviews
    igf1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    R&D Systems recombinant human igf 1
    (a) Experimental design of the conditioned-medium (CM) model. Mice received daily intraperitoneal injections of TRAMP-C1 CM or matched blank medium (Control) for 2 weeks; BM was collected after 1 or 2 weeks. (b) Flow-cytometric quantification of CCR3-positive neutrophils, CD8Temra cells, intermediate monocytes (intMono) and non-classical monocytes (ncMono) during niche establishment. Each dot represents one mouse; for CCR3 neutrophils, intMono and ncMono measurements, n = 6, 7 and 7 mice for Control, 1 week and 2 weeks groups, respectively. For CD8 T cells, n = 3 mice per group. (c) Representative multiplex immunofluorescence images of BM stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (d) Frequency of CCR3-positive Ly6G-positive neutrophils in BM, liver, lung, peripheral blood (PB) and spleen from sham-operated and orthotopic prostate-tumor-bearing mice. Each dot represents one mouse; n = 3 mice per group. (e) Differential expression in epithelial cells from primary prostate cancer versus normal prostate datasets; selected tumor-secreted factors are labeled. (f) Activity of <t>IGF1-,</t> CXCL8-and ERBB-family downstream gene modules across neutrophil states. (g) Representative immunohistochemical staining of IGF1 in normal prostate and prostate cancer tissues from patients with low/medium risk, high risk or established bone metastasis. Scale bar, 200 µm. (h) Quantification of prostate-tissue IGF1 staining and plasma IGF1 bioavailability across normal, low/medium-risk, high-risk and bone-metastatic prostate cancer groups. For tissue IGF1 staining, normal prostate, n = 15 patients; low/medium-risk PCa, n = 16; high-risk PCa, n = 21; bone-metastatic PCa, n = 11. For plasma IGF1 bioavailability, normal prostate, n = 6 patients; low/medium-risk PCa, n = 13; high-risk PCa, n = 14; bone-metastatic PCa, n = 10. (i) Paired plasma IGF1 bioavailability before and after radical prostatectomy (RP); n = 9 matched patient pairs. (j) IGF1 staining in primary prostate cancer tissues and plasma IGF1 bioavailability in patients with advanced localized PCa, stratified according to subsequent bone metastasis development during follow-up (non-BMets, remained free of bone metastasis; BMets, subsequently developed bone metastases). For tissue IGF1 staining, non-BMets, n = 36 patients; BMets, n = 33. For plasma IGF1 bioavailability, non-BMets, n = 18 patients; BMets, n = 8. (k) Flow-cytometric quantification of IGF1R mean fluorescence intensity (MFI) on neutrophils from PB, spleen and BM. Each dot represents one mouse; n = 4, 4 and 3 mice for PB, spleen and BM, respectively. (l) UMAP of epithelial cells in metastatic BM samples. Early and late subtypes were labeled. (m) Diffusion-map and RNA-velocity analysis of epithelial-subtype progression. (n) UMAP feature plots of IGF1 , COL5A2 , ACAD8 , FOS , FOSB and JUN . (o) Malignant epithelial cells from paired primary-prostate cancer and BM samples from patients M8 and M9, shown by cluster identity and tissue-specific density. (p) EMP scores across paired-sample epithelial clusters. (q) Patient-specific diffusion maps with RNA-velocity vectors, colored by cluster identity. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical significance was assessed using two-sided unpaired Student’s t-tests (b,d,h,j,k), a paired Student’s t-test (i), Fisher’s exact tests with multiple-testing correction (e). Student’s t-test P values were adjusted using the Benjamini-Hochberg method where multiple comparisons were performed.
    Recombinant Human Igf 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/Recombinant+Human+IGF-I%2FIGF-1+Protein%2C+CF/pm41896536-453-130-133
    Average 96 stars, based on 1 article reviews
    recombinant human igf 1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    R&D Systems recombinant mouse igf1
    (A) Differential gene expression analysis was performed comparing H2B–EGFP –positive and H2B–EGFP –negative cells within the MC-progenitor cluster identified by single-cell RNA sequencing. Genes are ranked by statistical significance. Foxm1 is significantly enriched in the H2B–EGFP –positive population, whereas Tgfb1 is enriched in the H2B–EGFP –negative population, indicating divergent transcriptional programs associated with Wnt activity. (B) Feature plots were generated to visualize expression of representative genes across mandibular condylar cartilage populations. Wnt-responsive cells show enriched expression of Foxm1 and IGF signaling–related genes ( <t>Igf1</t> , Igf1r , Igfbp4 , Igfbp7 ), whereas Wnt-low populations express Tgfb1 and related factors ( Igf2r , Igfbp5 , Igfbp6 ), supporting distinct signaling states. (C) Western blot analysis was performed in isolated Wnt-responsive cells transfected with control vector or constitutively active β-catenin (S33Y). Cells were stimulated with recombinant IGF1 for the indicated time points. β-catenin activation enhances Foxm1 expression and downstream mitogenic signaling, including ERK and IGF1R phosphorylation, indicating that β-catenin promotes proliferative signaling responses. (D) Co-immunoprecipitation was performed to assess interaction between β-catenin and Foxm1. Cell lysates immunoprecipitated with anti–β-catenin antibody show enrichment of Foxm1 compared with control IgG, indicating a physical association between β-catenin and Foxm1. (E,F) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Ctnnb1 fl/+ ;Foxm1 fl/+ compound heterozygous mice at P42. H&E staining reveals reduced fibrocartilage thickness, and Ki67 staining shows decreased proliferative activity, indicating cooperative effects of β-catenin and Foxm1 in maintaining fibrocartilage proliferation. Scale bar, 100 μm. (G) Quantification of fibrocartilage thickness and Ki67-positive cells was performed. Compound heterozygous mice show reduced fibrocartilage thickness and decreased proliferation compared with controls. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. (H,I) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Foxm1 fl/fl mice at P42. Foxm1 deletion results in marked condylar hypoplasia and reduced proliferative activity, indicating a critical role for Foxm1 in fibrocartilage growth. Scale bar, 100 μm. (J) Quantification of cartilage thickness and proliferative indices was performed in Foxm1 conditional knockout mice. Foxm1 deficiency significantly reduces cartilage growth and proliferation. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. Statistical significance was assessed using two-tailed Student’s t-test. n.s., not significant; **P < 0.01; ****P < 0.0001. Abbreviations: sz, superficial zone; fc, fibrocartilage zone; cc, chondrocartilage zone.
    Recombinant Mouse Igf1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/Recombinant+Mouse+IGF-I%2FIGF-1+Protein%2C+CF/bio_rxiv__64898__2026__03__25__714159-320-4-10
    Average 95 stars, based on 1 article reviews
    recombinant mouse igf1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress human recombinant igf 1 protein
    (A) Differential gene expression analysis was performed comparing H2B–EGFP –positive and H2B–EGFP –negative cells within the MC-progenitor cluster identified by single-cell RNA sequencing. Genes are ranked by statistical significance. Foxm1 is significantly enriched in the H2B–EGFP –positive population, whereas Tgfb1 is enriched in the H2B–EGFP –negative population, indicating divergent transcriptional programs associated with Wnt activity. (B) Feature plots were generated to visualize expression of representative genes across mandibular condylar cartilage populations. Wnt-responsive cells show enriched expression of Foxm1 and IGF signaling–related genes ( <t>Igf1</t> , Igf1r , Igfbp4 , Igfbp7 ), whereas Wnt-low populations express Tgfb1 and related factors ( Igf2r , Igfbp5 , Igfbp6 ), supporting distinct signaling states. (C) Western blot analysis was performed in isolated Wnt-responsive cells transfected with control vector or constitutively active β-catenin (S33Y). Cells were stimulated with recombinant IGF1 for the indicated time points. β-catenin activation enhances Foxm1 expression and downstream mitogenic signaling, including ERK and IGF1R phosphorylation, indicating that β-catenin promotes proliferative signaling responses. (D) Co-immunoprecipitation was performed to assess interaction between β-catenin and Foxm1. Cell lysates immunoprecipitated with anti–β-catenin antibody show enrichment of Foxm1 compared with control IgG, indicating a physical association between β-catenin and Foxm1. (E,F) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Ctnnb1 fl/+ ;Foxm1 fl/+ compound heterozygous mice at P42. H&E staining reveals reduced fibrocartilage thickness, and Ki67 staining shows decreased proliferative activity, indicating cooperative effects of β-catenin and Foxm1 in maintaining fibrocartilage proliferation. Scale bar, 100 μm. (G) Quantification of fibrocartilage thickness and Ki67-positive cells was performed. Compound heterozygous mice show reduced fibrocartilage thickness and decreased proliferation compared with controls. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. (H,I) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Foxm1 fl/fl mice at P42. Foxm1 deletion results in marked condylar hypoplasia and reduced proliferative activity, indicating a critical role for Foxm1 in fibrocartilage growth. Scale bar, 100 μm. (J) Quantification of cartilage thickness and proliferative indices was performed in Foxm1 conditional knockout mice. Foxm1 deficiency significantly reduces cartilage growth and proliferation. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. Statistical significance was assessed using two-tailed Student’s t-test. n.s., not significant; **P < 0.01; ****P < 0.0001. Abbreviations: sz, superficial zone; fc, fibrocartilage zone; cc, chondrocartilage zone.
    Human Recombinant Igf 1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/ATP5F1A%2C+Human/pmc13006418-68-0-5
    Average 94 stars, based on 1 article reviews
    human recombinant igf 1 protein - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    R&D Systems igf 1
    (A) Differential gene expression analysis was performed comparing H2B–EGFP –positive and H2B–EGFP –negative cells within the MC-progenitor cluster identified by single-cell RNA sequencing. Genes are ranked by statistical significance. Foxm1 is significantly enriched in the H2B–EGFP –positive population, whereas Tgfb1 is enriched in the H2B–EGFP –negative population, indicating divergent transcriptional programs associated with Wnt activity. (B) Feature plots were generated to visualize expression of representative genes across mandibular condylar cartilage populations. Wnt-responsive cells show enriched expression of Foxm1 and IGF signaling–related genes ( <t>Igf1</t> , Igf1r , Igfbp4 , Igfbp7 ), whereas Wnt-low populations express Tgfb1 and related factors ( Igf2r , Igfbp5 , Igfbp6 ), supporting distinct signaling states. (C) Western blot analysis was performed in isolated Wnt-responsive cells transfected with control vector or constitutively active β-catenin (S33Y). Cells were stimulated with recombinant IGF1 for the indicated time points. β-catenin activation enhances Foxm1 expression and downstream mitogenic signaling, including ERK and IGF1R phosphorylation, indicating that β-catenin promotes proliferative signaling responses. (D) Co-immunoprecipitation was performed to assess interaction between β-catenin and Foxm1. Cell lysates immunoprecipitated with anti–β-catenin antibody show enrichment of Foxm1 compared with control IgG, indicating a physical association between β-catenin and Foxm1. (E,F) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Ctnnb1 fl/+ ;Foxm1 fl/+ compound heterozygous mice at P42. H&E staining reveals reduced fibrocartilage thickness, and Ki67 staining shows decreased proliferative activity, indicating cooperative effects of β-catenin and Foxm1 in maintaining fibrocartilage proliferation. Scale bar, 100 μm. (G) Quantification of fibrocartilage thickness and Ki67-positive cells was performed. Compound heterozygous mice show reduced fibrocartilage thickness and decreased proliferation compared with controls. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. (H,I) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Foxm1 fl/fl mice at P42. Foxm1 deletion results in marked condylar hypoplasia and reduced proliferative activity, indicating a critical role for Foxm1 in fibrocartilage growth. Scale bar, 100 μm. (J) Quantification of cartilage thickness and proliferative indices was performed in Foxm1 conditional knockout mice. Foxm1 deficiency significantly reduces cartilage growth and proliferation. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. Statistical significance was assessed using two-tailed Student’s t-test. n.s., not significant; **P < 0.01; ****P < 0.0001. Abbreviations: sz, superficial zone; fc, fibrocartilage zone; cc, chondrocartilage zone.
    Igf 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+igf+1/Recombinant+Human+IGF-I%2FIGF-1+Protein%2C+CF/bio_rxiv__64898__2026__03__13__711696-188-11-12
    Average 96 stars, based on 1 article reviews
    igf 1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    (a) Experimental design of the conditioned-medium (CM) model. Mice received daily intraperitoneal injections of TRAMP-C1 CM or matched blank medium (Control) for 2 weeks; BM was collected after 1 or 2 weeks. (b) Flow-cytometric quantification of CCR3-positive neutrophils, CD8Temra cells, intermediate monocytes (intMono) and non-classical monocytes (ncMono) during niche establishment. Each dot represents one mouse; for CCR3 neutrophils, intMono and ncMono measurements, n = 6, 7 and 7 mice for Control, 1 week and 2 weeks groups, respectively. For CD8 T cells, n = 3 mice per group. (c) Representative multiplex immunofluorescence images of BM stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (d) Frequency of CCR3-positive Ly6G-positive neutrophils in BM, liver, lung, peripheral blood (PB) and spleen from sham-operated and orthotopic prostate-tumor-bearing mice. Each dot represents one mouse; n = 3 mice per group. (e) Differential expression in epithelial cells from primary prostate cancer versus normal prostate datasets; selected tumor-secreted factors are labeled. (f) Activity of IGF1-, CXCL8-and ERBB-family downstream gene modules across neutrophil states. (g) Representative immunohistochemical staining of IGF1 in normal prostate and prostate cancer tissues from patients with low/medium risk, high risk or established bone metastasis. Scale bar, 200 µm. (h) Quantification of prostate-tissue IGF1 staining and plasma IGF1 bioavailability across normal, low/medium-risk, high-risk and bone-metastatic prostate cancer groups. For tissue IGF1 staining, normal prostate, n = 15 patients; low/medium-risk PCa, n = 16; high-risk PCa, n = 21; bone-metastatic PCa, n = 11. For plasma IGF1 bioavailability, normal prostate, n = 6 patients; low/medium-risk PCa, n = 13; high-risk PCa, n = 14; bone-metastatic PCa, n = 10. (i) Paired plasma IGF1 bioavailability before and after radical prostatectomy (RP); n = 9 matched patient pairs. (j) IGF1 staining in primary prostate cancer tissues and plasma IGF1 bioavailability in patients with advanced localized PCa, stratified according to subsequent bone metastasis development during follow-up (non-BMets, remained free of bone metastasis; BMets, subsequently developed bone metastases). For tissue IGF1 staining, non-BMets, n = 36 patients; BMets, n = 33. For plasma IGF1 bioavailability, non-BMets, n = 18 patients; BMets, n = 8. (k) Flow-cytometric quantification of IGF1R mean fluorescence intensity (MFI) on neutrophils from PB, spleen and BM. Each dot represents one mouse; n = 4, 4 and 3 mice for PB, spleen and BM, respectively. (l) UMAP of epithelial cells in metastatic BM samples. Early and late subtypes were labeled. (m) Diffusion-map and RNA-velocity analysis of epithelial-subtype progression. (n) UMAP feature plots of IGF1 , COL5A2 , ACAD8 , FOS , FOSB and JUN . (o) Malignant epithelial cells from paired primary-prostate cancer and BM samples from patients M8 and M9, shown by cluster identity and tissue-specific density. (p) EMP scores across paired-sample epithelial clusters. (q) Patient-specific diffusion maps with RNA-velocity vectors, colored by cluster identity. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical significance was assessed using two-sided unpaired Student’s t-tests (b,d,h,j,k), a paired Student’s t-test (i), Fisher’s exact tests with multiple-testing correction (e). Student’s t-test P values were adjusted using the Benjamini-Hochberg method where multiple comparisons were performed.

    Journal: bioRxiv

    Article Title: Neutrophils orchestrate pre-metastatic immunosuppressive bone marrow remodeling during prostate cancer metastasis

    doi: 10.64898/2026.10.08.757800

    Figure Lengend Snippet: (a) Experimental design of the conditioned-medium (CM) model. Mice received daily intraperitoneal injections of TRAMP-C1 CM or matched blank medium (Control) for 2 weeks; BM was collected after 1 or 2 weeks. (b) Flow-cytometric quantification of CCR3-positive neutrophils, CD8Temra cells, intermediate monocytes (intMono) and non-classical monocytes (ncMono) during niche establishment. Each dot represents one mouse; for CCR3 neutrophils, intMono and ncMono measurements, n = 6, 7 and 7 mice for Control, 1 week and 2 weeks groups, respectively. For CD8 T cells, n = 3 mice per group. (c) Representative multiplex immunofluorescence images of BM stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (d) Frequency of CCR3-positive Ly6G-positive neutrophils in BM, liver, lung, peripheral blood (PB) and spleen from sham-operated and orthotopic prostate-tumor-bearing mice. Each dot represents one mouse; n = 3 mice per group. (e) Differential expression in epithelial cells from primary prostate cancer versus normal prostate datasets; selected tumor-secreted factors are labeled. (f) Activity of IGF1-, CXCL8-and ERBB-family downstream gene modules across neutrophil states. (g) Representative immunohistochemical staining of IGF1 in normal prostate and prostate cancer tissues from patients with low/medium risk, high risk or established bone metastasis. Scale bar, 200 µm. (h) Quantification of prostate-tissue IGF1 staining and plasma IGF1 bioavailability across normal, low/medium-risk, high-risk and bone-metastatic prostate cancer groups. For tissue IGF1 staining, normal prostate, n = 15 patients; low/medium-risk PCa, n = 16; high-risk PCa, n = 21; bone-metastatic PCa, n = 11. For plasma IGF1 bioavailability, normal prostate, n = 6 patients; low/medium-risk PCa, n = 13; high-risk PCa, n = 14; bone-metastatic PCa, n = 10. (i) Paired plasma IGF1 bioavailability before and after radical prostatectomy (RP); n = 9 matched patient pairs. (j) IGF1 staining in primary prostate cancer tissues and plasma IGF1 bioavailability in patients with advanced localized PCa, stratified according to subsequent bone metastasis development during follow-up (non-BMets, remained free of bone metastasis; BMets, subsequently developed bone metastases). For tissue IGF1 staining, non-BMets, n = 36 patients; BMets, n = 33. For plasma IGF1 bioavailability, non-BMets, n = 18 patients; BMets, n = 8. (k) Flow-cytometric quantification of IGF1R mean fluorescence intensity (MFI) on neutrophils from PB, spleen and BM. Each dot represents one mouse; n = 4, 4 and 3 mice for PB, spleen and BM, respectively. (l) UMAP of epithelial cells in metastatic BM samples. Early and late subtypes were labeled. (m) Diffusion-map and RNA-velocity analysis of epithelial-subtype progression. (n) UMAP feature plots of IGF1 , COL5A2 , ACAD8 , FOS , FOSB and JUN . (o) Malignant epithelial cells from paired primary-prostate cancer and BM samples from patients M8 and M9, shown by cluster identity and tissue-specific density. (p) EMP scores across paired-sample epithelial clusters. (q) Patient-specific diffusion maps with RNA-velocity vectors, colored by cluster identity. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical significance was assessed using two-sided unpaired Student’s t-tests (b,d,h,j,k), a paired Student’s t-test (i), Fisher’s exact tests with multiple-testing correction (e). Student’s t-test P values were adjusted using the Benjamini-Hochberg method where multiple comparisons were performed.

    Article Snippet: Purified BM neutrophils were treated with saline vehicle (Control) or recombinant IGF1 (100 ng/ml; MCE, HY-P70698A).

    Techniques: Control, Multiplex Assay, Immunofluorescence, Staining, Quantitative Proteomics, Labeling, Activity Assay, Immunohistochemical staining, Tissue, Clinical Proteomics, Fluorescence, Diffusion-based Assay, Analysis

    (a) Heatmap of genes differentially expressed in control and IGF1-treated mouse BM neutrophils; values are scaled expressions. Two mice were analysed per group, with each mouse serving as an independent biological replicate. (b) Gene-set enrichment analysis of the TAN signature in IGF1-treated versus control neutrophils using the RNA-seq data shown in a (n = 2 mice per group). (c) Representative immunofluorescence images of peripheral-blood and BM neutrophils from control- or IGF1-treated mice stained for DAPI, CD274, Ly6G and CCR3. Scale bars, 10 µm. (d) Frequencies of CCR3-positive and CD274-positive neutrophils in peripheral blood and BM; n = 3 mice per group. (e) Transcription-factor motifs enriched in accessible chromatin after IGF1 stimulation. n = 2 biologically independent neutrophil preparations per group. (f) Intersection of IGF1-upregulated genes (RNA-seq), IGF1-regulated transcription factors (ATAC-seq) and TAN-upregulated genes (scRNA-seq), identifying KLF4 as a candidate regulator. (g) KLF4 MFI in neutrophils after IGF1 stimulation with or without MAPK/ERK inhibition; n = 3 biologically independent samples per group. (h) ChIP-qPCR analysis of c-Myc occupancy at the KLF4 promoter after IGF1 stimulation; normal IgG served as the negative control. n = 3 biologically independent samples per group. (i) Experimental design for IGF1-induced BM preconditioning in mice receiving matched vehicle (Control), IGF1 or IGF1 plus the IGF1R inhibitor picropodophyllin (PPP). (j) CCR3 and ICAM1 MFIs in BM neutrophils after the indicated treatments; n = 6 mice per group. (k) Representative BM immunofluorescence images stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (l) Experimental design of the CM-induced BM-preconditioning model using matched blank medium (Control), wild-type TRAMP-C1 conditioned-medium (WT CM), Igf1-knockdown CM (Igf1-KD CM) or wild-type CM combined with an IGF1R-blocking antibody. (m) Frequencies of CCR3-positive neutrophils, PD-1-positive CD8 T cells and Tregs after the indicated CM treatments; n = 3 mice per group. (n) Experimental design for analysis of IGF1-induced BM remodeling in neutrophil-specific Igf1r conditional-knockout (cKO) mice and littermate controls. (o) CD274, CCR3 and ICAM1 MFIs in neutrophils, intermediate-monocyte frequency and CD8Temra frequency in control and cKO mice after IGF1 treatment; n = 3 mice per group. (p) Design of the mouse BM scRNA-seq experiment comprising saline-control, IGF1-induced HMP-like, and IGF1-preconditioned TRAMP-C1 metastatic groups. For each experimental group, BM cells from three mice were pooled to generate one scRNA-seq sample. (q) UMAP of all mouse BM cells, colored by major cell type. (r) UMAP of mouse neutrophil states with group-specific embeddings. (s) Human-derived TAN signature scores across mouse neutrophil states. (t) Differential abundance of mouse neutrophil states across experimental groups. Color indicates the log odds ratio, and “+” or “-” denotes significant enrichment or depletion, respectively. (u) UMAP of mouse BM CD8 T cell subtypes with group-specific embeddings. (v) Differential abundance of CD8 T cell subtypes across experimental groups. (w) IL-1β-induced signature scores in CD8Temra cells across saline-control, IGF1-induced HMP and TRAMP-C1 metastatic groups. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical comparisons in panels d, g, h, j, m and o were performed using two-sided Student’s t-tests. P values were adjusted using the Benjamini–Hochberg method where multiple comparisons were performed. For the GSEA in panel b, nominal P values and normalized enrichment scores are shown.

    Journal: bioRxiv

    Article Title: Neutrophils orchestrate pre-metastatic immunosuppressive bone marrow remodeling during prostate cancer metastasis

    doi: 10.64898/2026.10.08.757800

    Figure Lengend Snippet: (a) Heatmap of genes differentially expressed in control and IGF1-treated mouse BM neutrophils; values are scaled expressions. Two mice were analysed per group, with each mouse serving as an independent biological replicate. (b) Gene-set enrichment analysis of the TAN signature in IGF1-treated versus control neutrophils using the RNA-seq data shown in a (n = 2 mice per group). (c) Representative immunofluorescence images of peripheral-blood and BM neutrophils from control- or IGF1-treated mice stained for DAPI, CD274, Ly6G and CCR3. Scale bars, 10 µm. (d) Frequencies of CCR3-positive and CD274-positive neutrophils in peripheral blood and BM; n = 3 mice per group. (e) Transcription-factor motifs enriched in accessible chromatin after IGF1 stimulation. n = 2 biologically independent neutrophil preparations per group. (f) Intersection of IGF1-upregulated genes (RNA-seq), IGF1-regulated transcription factors (ATAC-seq) and TAN-upregulated genes (scRNA-seq), identifying KLF4 as a candidate regulator. (g) KLF4 MFI in neutrophils after IGF1 stimulation with or without MAPK/ERK inhibition; n = 3 biologically independent samples per group. (h) ChIP-qPCR analysis of c-Myc occupancy at the KLF4 promoter after IGF1 stimulation; normal IgG served as the negative control. n = 3 biologically independent samples per group. (i) Experimental design for IGF1-induced BM preconditioning in mice receiving matched vehicle (Control), IGF1 or IGF1 plus the IGF1R inhibitor picropodophyllin (PPP). (j) CCR3 and ICAM1 MFIs in BM neutrophils after the indicated treatments; n = 6 mice per group. (k) Representative BM immunofluorescence images stained for DAPI, CCR3 and Ly6G. Scale bars, 50 µm in the main images and 5 µm in the insets. (l) Experimental design of the CM-induced BM-preconditioning model using matched blank medium (Control), wild-type TRAMP-C1 conditioned-medium (WT CM), Igf1-knockdown CM (Igf1-KD CM) or wild-type CM combined with an IGF1R-blocking antibody. (m) Frequencies of CCR3-positive neutrophils, PD-1-positive CD8 T cells and Tregs after the indicated CM treatments; n = 3 mice per group. (n) Experimental design for analysis of IGF1-induced BM remodeling in neutrophil-specific Igf1r conditional-knockout (cKO) mice and littermate controls. (o) CD274, CCR3 and ICAM1 MFIs in neutrophils, intermediate-monocyte frequency and CD8Temra frequency in control and cKO mice after IGF1 treatment; n = 3 mice per group. (p) Design of the mouse BM scRNA-seq experiment comprising saline-control, IGF1-induced HMP-like, and IGF1-preconditioned TRAMP-C1 metastatic groups. For each experimental group, BM cells from three mice were pooled to generate one scRNA-seq sample. (q) UMAP of all mouse BM cells, colored by major cell type. (r) UMAP of mouse neutrophil states with group-specific embeddings. (s) Human-derived TAN signature scores across mouse neutrophil states. (t) Differential abundance of mouse neutrophil states across experimental groups. Color indicates the log odds ratio, and “+” or “-” denotes significant enrichment or depletion, respectively. (u) UMAP of mouse BM CD8 T cell subtypes with group-specific embeddings. (v) Differential abundance of CD8 T cell subtypes across experimental groups. (w) IL-1β-induced signature scores in CD8Temra cells across saline-control, IGF1-induced HMP and TRAMP-C1 metastatic groups. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Statistical comparisons in panels d, g, h, j, m and o were performed using two-sided Student’s t-tests. P values were adjusted using the Benjamini–Hochberg method where multiple comparisons were performed. For the GSEA in panel b, nominal P values and normalized enrichment scores are shown.

    Article Snippet: Purified BM neutrophils were treated with saline vehicle (Control) or recombinant IGF1 (100 ng/ml; MCE, HY-P70698A).

    Techniques: Control, Analysis, RNA Sequencing, Immunofluorescence, Staining, Inhibition, ChIP-qPCR, Negative Control, Knockdown, Blocking Assay, Gene Knockout, Saline, Derivative Assay, Oligomer Restriction

    (a) Experimental design for testing whether conditioned-medium (CM)-induced BM preconditioning promotes bone metastasis and whether PPP prevents this effect. Mice received matched blank medium (Control), wild-type TRAMP-C1 CM or CM plus PPP before intracardiac TRAMP-C1 injection. (b) Experimental design for testing whether recombinant IGF1-induced BM preconditioning promotes bone metastasis and whether PPP prevents this effect. Control mice received matched IGF1 and PPP vehicles. (c, d) Bone-metastasis-free curves and longitudinal bone bioluminescence imaging (BLI) signals after CM (c) or IGF1 (d) preconditioning, with or without PPP. For longitudinal BLI analyses, the area under the curve (AUC) was calculated for each mouse from ln(signal + 1)-transformed serial BLI measurements, and per-mouse AUC values were compared between groups; n = 10 mice per group. P 1 denotes Control versus CM in c and Control versus IGF1 in d; P 2 denotes CM versus CM plus PPP in c and IGF1 versus IGF1 plus PPP in d. (e) Experimental design using neutrophil-specific Igf1r conditional-knockout (cKO) mice and littermate controls to evaluate IGF1-induced BM preconditioning and subsequent bone metastasis. (f) Bone-metastasis-free curves and longitudinal bone BLI signals in control and cKO mice. BLI signals were natural-log transformed as ln(signal + 1); n = 10 mice per group. (g) Experimental design of the metastatic model evaluating Control, anti-IGF1R, anti-PD-1 or combined anti-IGF1R plus anti-PD-1 treatment. Control mice received matched saline. (h) Bone-metastasis-free curves and longitudinal bone BLI signals across treatment groups. BLI signals were natural-log transformed as ln(signal + 1); n = 10 mice per group. P values for the prespecified pairwise comparisons are shown in the panel: P 1, P 2 and P 3 denote Control versus Combination, Saline versus anti-IGF1R and Saline versus anti-PD-1, respectively. (i) Representative haematoxylin-and-eosin-stained bone sections from control, anti-IGF1R-, anti-PD-1- and combination-treated mice. Dashed lines outline tumor regions (T); B denotes bone. Scale bar, 400 µm. (j) Quantification of tumor area in the indicated treatment groups; each dot represents one mouse. (k) Frequencies of CCR3-positive neutrophils, IFNG-positive and PD1-positive CD8 T cells, and Tregs, together with BM IL-1β concentrations, across treatment groups; n = 3 mice per group. (l) Flowchart of the investigator-initiated trial of teprotumumab plus tislelizumab in metastatic castration-resistant prostate cancer; seven patients were enrolled and received treatment; one subsequently withdrew from the study. (m) Best percentage change in serum prostate-specific antigen (PSA) from baseline. (n) PSA progression-free survival from the first dose. (o) Representative axial PET/CT images before treatment and at day 84. (p) Best percentage change in serum alkaline phosphatase (ALP) from baseline. (q) Patient-reported pain outcomes at days 28, 56 and 84 after the first dose, categorized as improved, stable or worse relative to the immediately preceding assessment (day 28 versus baseline, day 56 versus day 28 and day 84 versus day 56); n = 6 evaluable patients at each time point. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Bone-metastasis-free curves were compared using log-rank tests. Longitudinal BLI data were compared using a two-sided Welch’s t-test. Pairwise cellular or histological comparisons were analyzed using two-sided Student’s t-tests, with Benjamini-Hochberg adjustment where multiple comparisons were performed. Exact P values are shown in the panels.

    Journal: bioRxiv

    Article Title: Neutrophils orchestrate pre-metastatic immunosuppressive bone marrow remodeling during prostate cancer metastasis

    doi: 10.64898/2026.10.08.757800

    Figure Lengend Snippet: (a) Experimental design for testing whether conditioned-medium (CM)-induced BM preconditioning promotes bone metastasis and whether PPP prevents this effect. Mice received matched blank medium (Control), wild-type TRAMP-C1 CM or CM plus PPP before intracardiac TRAMP-C1 injection. (b) Experimental design for testing whether recombinant IGF1-induced BM preconditioning promotes bone metastasis and whether PPP prevents this effect. Control mice received matched IGF1 and PPP vehicles. (c, d) Bone-metastasis-free curves and longitudinal bone bioluminescence imaging (BLI) signals after CM (c) or IGF1 (d) preconditioning, with or without PPP. For longitudinal BLI analyses, the area under the curve (AUC) was calculated for each mouse from ln(signal + 1)-transformed serial BLI measurements, and per-mouse AUC values were compared between groups; n = 10 mice per group. P 1 denotes Control versus CM in c and Control versus IGF1 in d; P 2 denotes CM versus CM plus PPP in c and IGF1 versus IGF1 plus PPP in d. (e) Experimental design using neutrophil-specific Igf1r conditional-knockout (cKO) mice and littermate controls to evaluate IGF1-induced BM preconditioning and subsequent bone metastasis. (f) Bone-metastasis-free curves and longitudinal bone BLI signals in control and cKO mice. BLI signals were natural-log transformed as ln(signal + 1); n = 10 mice per group. (g) Experimental design of the metastatic model evaluating Control, anti-IGF1R, anti-PD-1 or combined anti-IGF1R plus anti-PD-1 treatment. Control mice received matched saline. (h) Bone-metastasis-free curves and longitudinal bone BLI signals across treatment groups. BLI signals were natural-log transformed as ln(signal + 1); n = 10 mice per group. P values for the prespecified pairwise comparisons are shown in the panel: P 1, P 2 and P 3 denote Control versus Combination, Saline versus anti-IGF1R and Saline versus anti-PD-1, respectively. (i) Representative haematoxylin-and-eosin-stained bone sections from control, anti-IGF1R-, anti-PD-1- and combination-treated mice. Dashed lines outline tumor regions (T); B denotes bone. Scale bar, 400 µm. (j) Quantification of tumor area in the indicated treatment groups; each dot represents one mouse. (k) Frequencies of CCR3-positive neutrophils, IFNG-positive and PD1-positive CD8 T cells, and Tregs, together with BM IL-1β concentrations, across treatment groups; n = 3 mice per group. (l) Flowchart of the investigator-initiated trial of teprotumumab plus tislelizumab in metastatic castration-resistant prostate cancer; seven patients were enrolled and received treatment; one subsequently withdrew from the study. (m) Best percentage change in serum prostate-specific antigen (PSA) from baseline. (n) PSA progression-free survival from the first dose. (o) Representative axial PET/CT images before treatment and at day 84. (p) Best percentage change in serum alkaline phosphatase (ALP) from baseline. (q) Patient-reported pain outcomes at days 28, 56 and 84 after the first dose, categorized as improved, stable or worse relative to the immediately preceding assessment (day 28 versus baseline, day 56 versus day 28 and day 84 versus day 56); n = 6 evaluable patients at each time point. Unless otherwise indicated, bar plots with error bars show mean ± s.d. Bone-metastasis-free curves were compared using log-rank tests. Longitudinal BLI data were compared using a two-sided Welch’s t-test. Pairwise cellular or histological comparisons were analyzed using two-sided Student’s t-tests, with Benjamini-Hochberg adjustment where multiple comparisons were performed. Exact P values are shown in the panels.

    Article Snippet: Purified BM neutrophils were treated with saline vehicle (Control) or recombinant IGF1 (100 ng/ml; MCE, HY-P70698A).

    Techniques: Control, Injection, Recombinant, Imaging, Transformation Assay, Gene Knockout, Saline, Staining, Positron Emission Tomography-Computed Tomography

    (A) Differential gene expression analysis was performed comparing H2B–EGFP –positive and H2B–EGFP –negative cells within the MC-progenitor cluster identified by single-cell RNA sequencing. Genes are ranked by statistical significance. Foxm1 is significantly enriched in the H2B–EGFP –positive population, whereas Tgfb1 is enriched in the H2B–EGFP –negative population, indicating divergent transcriptional programs associated with Wnt activity. (B) Feature plots were generated to visualize expression of representative genes across mandibular condylar cartilage populations. Wnt-responsive cells show enriched expression of Foxm1 and IGF signaling–related genes ( Igf1 , Igf1r , Igfbp4 , Igfbp7 ), whereas Wnt-low populations express Tgfb1 and related factors ( Igf2r , Igfbp5 , Igfbp6 ), supporting distinct signaling states. (C) Western blot analysis was performed in isolated Wnt-responsive cells transfected with control vector or constitutively active β-catenin (S33Y). Cells were stimulated with recombinant IGF1 for the indicated time points. β-catenin activation enhances Foxm1 expression and downstream mitogenic signaling, including ERK and IGF1R phosphorylation, indicating that β-catenin promotes proliferative signaling responses. (D) Co-immunoprecipitation was performed to assess interaction between β-catenin and Foxm1. Cell lysates immunoprecipitated with anti–β-catenin antibody show enrichment of Foxm1 compared with control IgG, indicating a physical association between β-catenin and Foxm1. (E,F) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Ctnnb1 fl/+ ;Foxm1 fl/+ compound heterozygous mice at P42. H&E staining reveals reduced fibrocartilage thickness, and Ki67 staining shows decreased proliferative activity, indicating cooperative effects of β-catenin and Foxm1 in maintaining fibrocartilage proliferation. Scale bar, 100 μm. (G) Quantification of fibrocartilage thickness and Ki67-positive cells was performed. Compound heterozygous mice show reduced fibrocartilage thickness and decreased proliferation compared with controls. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. (H,I) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Foxm1 fl/fl mice at P42. Foxm1 deletion results in marked condylar hypoplasia and reduced proliferative activity, indicating a critical role for Foxm1 in fibrocartilage growth. Scale bar, 100 μm. (J) Quantification of cartilage thickness and proliferative indices was performed in Foxm1 conditional knockout mice. Foxm1 deficiency significantly reduces cartilage growth and proliferation. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. Statistical significance was assessed using two-tailed Student’s t-test. n.s., not significant; **P < 0.01; ****P < 0.0001. Abbreviations: sz, superficial zone; fc, fibrocartilage zone; cc, chondrocartilage zone.

    Journal: bioRxiv

    Article Title: A Wnt-responsive fibrocartilage progenitor system coordinates postnatal mandibular condylar cartilage growth

    doi: 10.64898/2026.03.25.714159

    Figure Lengend Snippet: (A) Differential gene expression analysis was performed comparing H2B–EGFP –positive and H2B–EGFP –negative cells within the MC-progenitor cluster identified by single-cell RNA sequencing. Genes are ranked by statistical significance. Foxm1 is significantly enriched in the H2B–EGFP –positive population, whereas Tgfb1 is enriched in the H2B–EGFP –negative population, indicating divergent transcriptional programs associated with Wnt activity. (B) Feature plots were generated to visualize expression of representative genes across mandibular condylar cartilage populations. Wnt-responsive cells show enriched expression of Foxm1 and IGF signaling–related genes ( Igf1 , Igf1r , Igfbp4 , Igfbp7 ), whereas Wnt-low populations express Tgfb1 and related factors ( Igf2r , Igfbp5 , Igfbp6 ), supporting distinct signaling states. (C) Western blot analysis was performed in isolated Wnt-responsive cells transfected with control vector or constitutively active β-catenin (S33Y). Cells were stimulated with recombinant IGF1 for the indicated time points. β-catenin activation enhances Foxm1 expression and downstream mitogenic signaling, including ERK and IGF1R phosphorylation, indicating that β-catenin promotes proliferative signaling responses. (D) Co-immunoprecipitation was performed to assess interaction between β-catenin and Foxm1. Cell lysates immunoprecipitated with anti–β-catenin antibody show enrichment of Foxm1 compared with control IgG, indicating a physical association between β-catenin and Foxm1. (E,F) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Ctnnb1 fl/+ ;Foxm1 fl/+ compound heterozygous mice at P42. H&E staining reveals reduced fibrocartilage thickness, and Ki67 staining shows decreased proliferative activity, indicating cooperative effects of β-catenin and Foxm1 in maintaining fibrocartilage proliferation. Scale bar, 100 μm. (G) Quantification of fibrocartilage thickness and Ki67-positive cells was performed. Compound heterozygous mice show reduced fibrocartilage thickness and decreased proliferation compared with controls. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. (H,I) Histological and immunofluorescence analyses were performed on mandibular condyles from control and Axin2 CreERT2 ;Foxm1 fl/fl mice at P42. Foxm1 deletion results in marked condylar hypoplasia and reduced proliferative activity, indicating a critical role for Foxm1 in fibrocartilage growth. Scale bar, 100 μm. (J) Quantification of cartilage thickness and proliferative indices was performed in Foxm1 conditional knockout mice. Foxm1 deficiency significantly reduces cartilage growth and proliferation. Data are presented as mean ± s.d. Each dot represents one biologically independent animal. Statistical significance was assessed using two-tailed Student’s t-test. n.s., not significant; **P < 0.01; ****P < 0.0001. Abbreviations: sz, superficial zone; fc, fibrocartilage zone; cc, chondrocartilage zone.

    Article Snippet: Cells were stimulated with recombinant mouse IGF1 (Cat No. 791-MG-050, R&D systems) for 0, 30, 60, or 180 min.

    Techniques: Gene Expression, Single Cell, RNA Sequencing, Activity Assay, Generated, Expressing, Western Blot, Isolation, Transfection, Control, Plasmid Preparation, Recombinant, Activation Assay, Phospho-proteomics, Immunoprecipitation, Immunofluorescence, Staining, Knock-Out, Two Tailed Test

    (A) RNAscope in situ hybridization showing Foxm1 transcript localization within the fibrocartilage compartment of the mandibular condyle. (B) RNAscope detection of Igf1 transcripts enriched in the superficial region of the fibrocartilage layer. (C) Violin plot comparing Foxm1 expression between H2B-EGFP –positive and H2B-EGFP –negative cells within the MC-progenitor cluster. Scale bars: 100 μm.

    Journal: bioRxiv

    Article Title: A Wnt-responsive fibrocartilage progenitor system coordinates postnatal mandibular condylar cartilage growth

    doi: 10.64898/2026.03.25.714159

    Figure Lengend Snippet: (A) RNAscope in situ hybridization showing Foxm1 transcript localization within the fibrocartilage compartment of the mandibular condyle. (B) RNAscope detection of Igf1 transcripts enriched in the superficial region of the fibrocartilage layer. (C) Violin plot comparing Foxm1 expression between H2B-EGFP –positive and H2B-EGFP –negative cells within the MC-progenitor cluster. Scale bars: 100 μm.

    Article Snippet: Cells were stimulated with recombinant mouse IGF1 (Cat No. 791-MG-050, R&D systems) for 0, 30, 60, or 180 min.

    Techniques: RNAscope, In Situ Hybridization, Expressing